Mapping Clinical Updates in Myelodysplastic Syndromes

Jorge Cortes, MD discusses the FDA approval of luspatercept-aamt has influenced first-line MDS management.

Jorge Cortes, MD, discusses the need to balance outcomes and quality of life in the treatment of anemia in low-risk myelodysplastic syndrome.

David Sallman, MD, discusses the clinical implications of the 2023 FDA approval of luspatercept for patients with very low– to intermediate-risk MDS.

Luspatercept generated high rates of durable transfusion independence for patients with lower-risk myelodysplastic syndrome in a real-world analysis.

Dr Garcia-Manero discusses findings from research in myelodysplastic syndromes that were presented at the 2024 EHA Congress.

Guillermo Garcia-Manero, MD, spotlights 3 key analyses of luspatercept in low-risk myelodysplastic syndrome presented at the 2024 EHA Congress.

Guillermo Garcia-Manero, MD, discusses the safety and impact of luspatercept on hematopoetic lineages in transfusion-dependent lower-risk MDS.

Luspatercept elicited superior erythroid response rates and duration of RBC transfusion independence compared with epoetin alfa in lower-risk MDS.